Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

[Iron overload and cardiotoxicity: from thalassemia to reperfusion damage].

Roghi A.

G Ital Cardiol (Rome). 2013 Jun;14(6):438-44. doi: 10.1714/1280.14157. Review. Italian.

PMID:
23748540
2.

Treatment of iron overload in thalassemia.

Cianciulli P.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:208-13. Review.

PMID:
19337180
3.

Assessment and treatment of cardiac iron overload in thalassemia.

Aessopos A, Farmakis D, Andreopoulos A, Tsironi M.

Hemoglobin. 2009;33 Suppl 1:S87-92. doi: 10.3109/03630260903347401. Review.

PMID:
20001638
4.

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.

Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R.

J Natl Compr Canc Netw. 2009 Dec 29;7 Suppl 9:S1-16.

PMID:
20064286
5.

[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].

Martín M, Estornell J, Orero M, Pérez JL, Ridocci F, Martínez V.

Rev Esp Cardiol. 2006 Jan;59(1):75-7. Spanish.

6.

Chelation therapy for iron overload.

Barton JC.

Curr Gastroenterol Rep. 2007 Mar;9(1):74-82. Review.

PMID:
17335681
7.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.

Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.

10.
11.

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

Porter JB, Shah FT.

Hematol Oncol Clin North Am. 2010 Dec;24(6):1109-30. doi: 10.1016/j.hoc.2010.08.015. Review.

PMID:
21075283
12.

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy.

Farmaki K, Gotsis E, Tzoumari I, Berdoukas V.

Eur J Haematol. 2008 Aug;81(2):157-9. doi: 10.1111/j.1600-0609.2008.01092.x. Epub 2008 May 6.

13.

Cardiovascular MRI in thalassemia major.

Wood JC, Noetzli L.

Ann N Y Acad Sci. 2010 Aug;1202:173-9. doi: 10.1111/j.1749-6632.2010.05571.x.

PMID:
20712790
14.

Iron chelation therapy for patients with myelodysplastic syndrome.

Yeh SP, Yang YS, Yao CY, Peng CT.

Hemoglobin. 2009;33(5):339-45. doi: 10.3109/03630260903212654. Review.

PMID:
19814680
15.

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.

Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9. doi: 10.1016/j.bcmd.2010.05.005. Epub 2010 Jun 17.

PMID:
20678715
16.

T2* magnetic resonance and myocardial iron in thalassemia.

Pennell DJ.

Ann N Y Acad Sci. 2005;1054:373-8. Review.

PMID:
16339685
17.

MRI and iron-overload cardiomyopathy in thalassaemia.

Pennell D.

Circulation. 2006 Mar 21;113(11):f43-4. No abstract available.

18.

Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.

Pathare A, Taher A, Daar S.

Ann Hematol. 2010 Apr;89(4):405-9. doi: 10.1007/s00277-009-0838-z. Epub 2009 Oct 2.

19.

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.

Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.

Br J Haematol. 2010 Feb;148(3):466-75. doi: 10.1111/j.1365-2141.2009.07970.x. Epub 2009 Nov 12.

PMID:
19912219
20.

Methods for noninvasive measurement of tissue iron in Cooley's anemia.

Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.

Ann N Y Acad Sci. 2005;1054:358-72.

PMID:
16339684

Supplemental Content

Support Center